Comparison
Both are GLP-1 receptor agonists approved for type 2 diabetes and obesity management. Semaglutide is the newer generation compound, offering a markedly longer half-life, less frequent dosing, greater reported weight loss depth, and an oral formulation option that liraglutide lacks.
| Attribute | Semaglutide | Liraglutide |
|---|---|---|
| Brand names | Ozempic (diabetes), Wegovy (obesity), Rybelsus (oral) | Victoza (diabetes), Saxenda (obesity) |
| Class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Mechanism | GLP-1 receptor agonism: satiety signalling, insulin secretion, gastric emptying delay | GLP-1 receptor agonism: satiety signalling, insulin secretion, gastric emptying delay |
| Half-life | ~7 days | ~13 hours |
| Dosing frequency | Once weekly (injectable); once daily (oral Rybelsus) | Once daily (injectable only) |
| Commonly reported doses | 0.25–2.4 mg/week SubQ; 3–14 mg/day oral | 0.6–3.0 mg/day SubQ |
| Routes | SubQ injection; oral tablet | SubQ injection only |
| Reported weight loss | ~15% body weight (Wegovy phase 3 trial) | ~8% body weight (Saxenda phase 3 trial) |
| Cardiovascular outcome data | SUSTAIN-6, SELECT trials: reduced MACE | LEADER trial: reduced MACE |
The most clinically significant difference between semaglutide and liraglutide is half-life, which directly drives dosing frequency. Liraglutide's half-life of approximately 13 hours requires daily subcutaneous injection to maintain steady-state plasma concentrations. Semaglutide's albumin-binding modifications extend its half-life to approximately 7 days, allowing once-weekly administration. For most patients and researchers, the shift from daily to weekly injection represents a substantial improvement in adherence and convenience.
Reported weight loss depth also differs. Phase 3 trials of semaglutide 2.4 mg weekly (the Wegovy formulation) reported approximately 15% mean body weight reduction over 68 weeks. Liraglutide 3.0 mg daily (Saxenda) reported approximately 8% mean body weight reduction in comparable trials. This difference has been attributed to semaglutide's more potent and sustained GLP-1 receptor engagement, though direct head-to-head comparative trials have been limited.
Semaglutide also offers an oral formulation (Rybelsus, approved for type 2 diabetes), making it the first GLP-1 receptor agonist available without injection. Oral semaglutide requires fasting administration under specific conditions to achieve adequate bioavailability, and the doses used orally (7–14 mg/day) are higher than injectable equivalents due to reduced absorption. Liraglutide has no approved oral formulation and has not been developed in that direction.
Both compounds are GLP-1 receptor agonists, meaning they mimic the endogenous incretin hormone glucagon-like peptide-1 at its receptor. GLP-1 receptor activation produces several coordinated metabolic effects: glucose-dependent stimulation of insulin secretion from pancreatic beta cells, suppression of glucagon from alpha cells, delay of gastric emptying (slowing nutrient absorption), and central nervous system signalling that promotes satiety and reduces appetite. The net effect is improved glycaemic control and, at higher doses, meaningful weight reduction.
The molecular distinction between the two lies in structural modifications designed to extend duration of action. Liraglutide incorporates a C-16 fatty acid chain that allows non-covalent binding to albumin, extending its half-life from the native GLP-1 half-life of approximately 2 minutes to approximately 13 hours. Semaglutide uses a C-18 fatty diacid chain with a longer linker, producing tighter albumin binding and substantially greater protease resistance, extending half-life to approximately 7 days. Both modifications result in sustained receptor engagement, but semaglutide's structural changes produce more potent and longer-lasting receptor activation.
Research has investigated both compounds for their potential role in:
Semaglutide has accumulated a broader research base across indications. The SELECT trial investigated semaglutide in individuals with established cardiovascular disease and obesity without diabetes, demonstrating cardiovascular benefit in that population. Research has also investigated semaglutide for its potential role in obstructive sleep apnea, kidney disease progression, and metabolic dysfunction-associated steatohepatitis (MASH). Liraglutide has a robust cardiovascular outcomes dataset from the LEADER trial and established use in paediatric obesity management in some regulatory jurisdictions.
Commonly reported doses for semaglutide depend on indication and formulation:
Commonly reported doses for liraglutide:
Injectable semaglutide and liraglutide are both administered subcutaneously into the abdomen, thigh, or upper arm. Site rotation is part of the commonly reported protocol for both. Oral semaglutide (Rybelsus) requires specific administration conditions: fasting state, consumption with no more than 120 mL of water, and a minimum 30-minute wait before eating, drinking, or taking other medications. These requirements reflect the peptide's absorption via the SNAC (sodium N-[8-(2-hydroxybenzoyl) aminocaprylate] carrier) system, which is sensitive to co-administration with food or liquids.
Reported side effects in research and anecdotal accounts include, for both compounds:
Both compounds carry class-level precautions regarding pancreatitis and thyroid C-cell effects observed in rodent studies. Oral semaglutide additionally carries a risk of gastrointestinal side effects related to the SNAC excipient. Given semaglutide's longer half-life, once a side effect begins during a weekly dose cycle, it typically persists longer than side effects from the daily-dosed liraglutide, which clear more rapidly between doses.
Semaglutide and liraglutide are not typically co-administered. Both act on the same receptor system (GLP-1 receptor), and combining them would not provide additive mechanistic benefit. Combining two GLP-1 agonists would substantially increase GI side effect burden with no established therapeutic gain. Researchers and clinicians generally select one compound or transition between them based on tolerability or efficacy considerations rather than co-administering both.
Research contexts commonly favour semaglutide when the investigation requires once-weekly dosing, when maximum reported weight loss depth is a primary outcome variable, or when an oral delivery route is preferred for patient convenience or research design. Its larger and more recent evidence base also supports its use in cardiovascular outcomes and emerging indication research.
Research contexts where liraglutide remains relevant include investigations requiring daily dosing precision, comparisons against the established Victoza/Saxenda literature, paediatric obesity research (where liraglutide has regulatory approval in some jurisdictions), and where the longer history of clinical use provides a more complete long-term safety dataset for comparison.
Phase 3 trial data reports substantially greater mean weight loss with semaglutide 2.4 mg weekly (~15%) compared to liraglutide 3.0 mg daily (~8%). This difference reflects both the more potent GLP-1 receptor engagement and the higher effective exposure achieved with semaglutide's structural modifications. However, individual responses vary, and tolerability differences between the two compounds also influence which produces better outcomes in a given research or clinical context.
Yes. Oral semaglutide (Rybelsus) is approved for type 2 diabetes management. It uses a proprietary SNAC absorption-enhancer technology to allow peptide absorption across the gastric mucosa. The oral formulation requires specific fasting administration conditions to achieve adequate bioavailability. No oral formulation of liraglutide is approved or in late-stage development.
Tirzepatide adds GIP receptor agonism to GLP-1 receptor activation, resulting in greater reported weight loss (~20% in phase 3 trials) compared to semaglutide. Both semaglutide and liraglutide are GLP-1 mono-agonists, meaning they target only the GLP-1 receptor. The incremental progression from liraglutide to semaglutide to tirzepatide reflects successive generations of metabolic peptide research.
Liraglutide has a longer clinical history, having been approved since 2010 for diabetes (Victoza) and 2014 for obesity (Saxenda). This provides a longer post-marketing safety observation period. Semaglutide (Ozempic approval: 2017; Wegovy: 2021) has a shorter post-marketing record but has accumulated substantial data rapidly given its widespread clinical adoption. Both compounds have extensive safety datasets relative to most investigational peptides.